Amundi’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
Other funds holding ESPR
MG
Amundi's ESPR Position: Q1 2021 in Review
Amundi sold out of Esperion Therapeutics (ESPR) in Q1 2021, closing a stake of 379,326 shares — an estimated $9.9M sold.
Amundi first reported a position in ESPR in Q3 2017 and held it in 14 quarters. The position peaked at $21.3M in Q1 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q1 2021.
- Amundi reported no remaining Esperion Therapeutics position as of Q1 2021 after selling out during the quarter.
- Amundi sold 379,326 Esperion Therapeutics shares in Q1 2021, an estimated $9.9M.
- Amundi first reported a position in Esperion Therapeutics in Q3 2017 and held it in 14 quarters.
- Amundi's Esperion Therapeutics position peaked at $21.3M in Q1 2018.
- 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2021.
Based on Amundi's 13F filing for Q1 2021, filed 17 May 2021.